Form POSASR Neumora Therapeutics,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- US stock futures rise on tech rebound before Nvidia, inflation tests
- Oil falls over 4% as investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- Six Flags to move headquarters from Charlotte to Arlington, Texas
Guggenheim Reiterates Buy Rating on Neumora Therapeutics (NMRA), PT $7
March 3, 2025 1:15 PM ESTGuggenheim analyst Yatin Suneja reiterated a Buy rating and $7.00 price target on Neumora Therapeutics (NASDAQ: NMRA)
The analyst comments "Key Message: Today NMRA reported 4Q24 financial results and pipeline updates. Our key highlights include: (1) NMRA has paused KOASTAL-2 and -3 studies of navacaprant (KOR antagonist) and plans to resume them in March 2025 after implementing a series of optimizations based on learnings from KOASTAL-1 (K-1; recall this study failed the primary endpoint - see HERE and HERE), including enhanced... More
Neumora Therapeutics (NMRA) PT Lowered to $6 at Stifel
March 3, 2025 9:16 AM ESTStifel analyst Paul Matteis lowered the price target on Neumora Therapeutics (NASDAQ: NMRA) to $6.00 (from $26.00) while maintaining a Buy rating.
The analyst comments "We remain Buy rated on NMRA, as we think the risk/reward on the KOSTAL-2/3 trials is... More
